{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:09:44Z","timestamp":1775693384339,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Governmental funding of clinical research within the Swedish NHS"},{"name":"Region of Scania R&D funding"},{"name":"The Foundation of the University Hospital of Lund"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ypmed.2019.04.021","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T20:10:09Z","timestamp":1556568609000},"page":"61-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Population-based primary HPV mRNA cervical screening compared with cytology screening"],"prefix":"10.1016","volume":"124","author":[{"given":"Ylva","family":"Lindroth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christer","family":"Borgfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunilla","family":"Thorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunilla","family":"Bodelsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-7286","authenticated-orcid":false,"given":"Ola","family":"Forslund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ypmed.2019.04.021_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/(SICI)1097-0142(19980225)84:1<5::AID-CNCR2>3.0.CO;2-Q","article-title":"Assessment of cytologic follow-up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions","volume":"84","author":"Alanen","year":"1998","journal-title":"Cancer"},{"issue":"Suppl. 5","key":"10.1016\/j.ypmed.2019.04.021_bb0010","doi-asserted-by":"crossref","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","article-title":"Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer","volume":"30","author":"Arbyn","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0015","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmi.2015.04.015","article-title":"Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?","volume":"21","author":"Arbyn","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ypmed.2019.04.021_bb0020","first-page":"817","article-title":"Genital human papillomavirus infections and cancer: memorandum from a WHO meeting","volume":"65","author":"Baker","year":"1987","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ypmed.2019.04.021_bb0025","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(07)61450-0","article-title":"Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial","volume":"370","author":"Bulkmans","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0030","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(11)70188-7","article-title":"Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study","volume":"12","author":"Castle","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2019.04.021_bb0035","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/dc.23930","article-title":"Human papillomavirus detection with genotyping by the cobas and Aptima assays: significant differences in HPV 16 detection?","volume":"46","author":"Chorny","year":"2018","journal-title":"Diagn. Cytopathol."},{"key":"10.1016\/j.ypmed.2019.04.021_bb0040","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0140-6736(95)91086-7","article-title":"Human papillomavirus testing in primary cervical screening","volume":"345","author":"Cuzick","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0045","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and north American studies on HPV testing in primary cervical cancer screening","volume":"119","author":"Cuzick","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0050","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cncy.21783","article-title":"Knowledge of the HPV status biases cytotechnologists' interpretation of Pap tests originally diagnosed as negative for intraepithelial lesion or malignancy","volume":"125","author":"Doxtader","year":"2017","journal-title":"Cancer Cytopathol."},{"issue":"5","key":"10.1016\/j.ypmed.2019.04.021_bb0055","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/ijc.31819","article-title":"HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri","volume":"144","author":"Forslund","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0060","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/bjc.1990.202","article-title":"Cytologic screening for cancer of the uterine cervix in Sweden evaluated by identification and simulation","volume":"61","author":"Gustafsson","year":"1990","journal-title":"Br. J. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ypmed.2019.04.021_bb0065","article-title":"A review of the clinical performance of the Aptima HPV assay","volume":"76","author":"Haedicke","year":"2016","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ypmed.2019.04.021_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189300","article-title":"HPV prevalence and HPV-related dysplasia in elderly women","volume":"13","author":"Hermansson","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0075","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1186\/s12885-016-2961-2","article-title":"HPV prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows","volume":"16","author":"Huijsmans","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0080","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1128\/JCM.01013-15","article-title":"Head-to-head comparison of the RNA-based Aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany","volume":"53","author":"Iftner","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ypmed.2019.04.021_bb0085","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01177-18","article-title":"Longitudinal clinical performance of the RNA-based Aptima human papillomavirus (AHPV) assay in comparison to the DNA-based hybrid capture 2 HPV test in two consecutive screening rounds with a 6-year interval in Germany","volume":"57","author":"Iftner","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ypmed.2019.04.021_bb0090","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/(SICI)1097-0215(19960315)65:6<768::AID-IJC10>3.0.CO;2-0","article-title":"Can papilloma virus testing be used to improve cervical cancer screening?","volume":"65","author":"Jenkins","year":"1996","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124460","article-title":"Presence of high-risk HPV mRNA in relation to future high-grade lesions among high-risk HPV DNA positive women with minor cytological abnormalities","volume":"10","author":"Johansson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0100","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1038\/bjc.2013.647","article-title":"Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland","volume":"109","author":"Leinonen","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0105","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/bjc.2016.216","article-title":"Screening women for cervical cancer carcinoma with a HPV mRNA test: first results from the Venice pilot program","volume":"115","author":"Maggino","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0110","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/ijc.30609","article-title":"Risk of high-grade precancerous lesions and invasive cancers in high-risk HPV-positive women with normal cervix or CIN 1 at baseline-A population-based cohort study","volume":"140","author":"Mittal","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0115","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1086\/516784","article-title":"A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion","volume":"195","author":"Plummer","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ypmed.2019.04.021_bb0120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1309\/AJCPHVD7MIP3FYVV","article-title":"Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study","volume":"144","author":"Reid","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ypmed.2019.04.021_bb0125","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ijc.26056","article-title":"Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening","volume":"130","author":"Rijkaart","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0135","series-title":"Current Care Program for Cervical Cancer Prevention","author":"Swedish-Regional-Cancer-Centers","year":"2017"},{"key":"10.1016\/j.ypmed.2019.04.021_bb0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ypmed.2019.04.021_bb0145","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/jnci\/92.9.690","article-title":"Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis","volume":"92","author":"zur Hausen","year":"2000","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743519301604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743519301604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:03:17Z","timestamp":1758794597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743519301604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":29,"alternative-id":["S0091743519301604"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2019.04.021","relation":{},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population-based primary HPV mRNA cervical screening compared with cytology screening","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2019.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}